Search PubMed⌕ Search

Biomedical subjects

R Verberckmoes

Publications and source records attributed to R Verberckmoes.

At least 37 records · Page 2Linked to original sources
PubMed1985

Serum transcortin levels in patients with chronic hemodialysis.

Patients with renal insufficiency who are hemodialyzed 3 times a week either through a cuprophane membrane or through a polyacrylonitrile (PAN) membrane have the same transcortin and cortisol levels as patients with renal insufficiency who are not dialyzed. Moreover, hemodialysis did not influence acutely the latter transcortin levels.

Acrylic Resins↗
PubMed1985

[Acute renal insufficiency: 1st manifestation of familial sarcoidosis].

We report an unusual case of sarcoidosis remarkable for: 1) The presentation as acute irreversible renal failure with interstitial granulomas and ischemic glomerular lesions. This leads to a discussion of the possibility of perivascular granulomas or the existence of a vasculitis. 2) The unusual localisation of other lesions in the stomach and cutaneous tissues with a necrotising epidermal vasculitis, unusual in sarcoidosis. 3) The existence, in the patient's mother, of nasal mucosal sarcoidosis and also a carrier of the B8 and DR3 antigens.

Acute Kidney Injury↗
PubMed1982

Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.

The influence of hemodialysis on plasma fenofibric acid kinetics has been investigated in patients with chronic renal failure given 300 mg of fenofibrate in a single oral dose. A very pronounced lengthening of the fenofibric acid plasma decay was observed in both hemodialyzed (n = 6) and nonhemodialyzed (n = 9) patients. Hemodialysis did not modify the plasma levels and the ultrafiltrates contained very small amounts of fenofibric acid. The repeated daily administration of 100 mg of fenofibrate during 2 weeks in 5 renal patients on regular hemodialysis resulted in increasing plasma levels and led to progressive cumulation of fenofibric acid. Plasma fenofibric acid conjugates could not be detected. No particular clinical side effects or increase of CPK, GOT, GPT were be observed.

Adult↗
PubMed1976

Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin.

During treatment with indomethacin in a patient with Bartter's syndrome, hypokalemia, high plasma renin concentration, hyperaldosteronism and decreased sensitivity to angiotensin infusion were corrected. A particular finding in the renal biopsy specimen was a marked hyperplasia of renomedullary interstitial cells which had characteristics similar to the cells known to produce renal prostaglandins. The hypothesis is formultated that the primary defect in this syndrome is related to hyperplasia of renomedullary interstitial cells and inappropriate release of renal prostaglandins giving rise to decreased sodium reabsorption, volume depletion and hypersecretion of renin and aldosterone.

Adult↗
PubMed1976

The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol.

A single oral dose of sotalol (160 mg) was administered to control subjects with normal renal function and patients with chronic renal failure in the interdialysis period to estimate the elimination kinetics of the drug. Sotalol concentrations in body fluids were measured fluorimetrically using a modified Garrett and Schnelle (1971) method. Mean plasma half-life (T 1/2) was approximately 5 h in normals, 42 h in patients off-dialysis. During haemodialysis the mean plasma half-time was on the average 7 hours. Comulative urinary excretion of the drug was considerably lower in the patient group: 9% of the dose in 48 h as opposed to 61% in normals. Comparison of sotalol concentrations in plasma versus ultrafiltrate from the coil kidney indicates that the drug in vivo is negligible bound to plasma proteins in remal patients. The net-lowering effect of a 6 to 7 h haemodialysis on the plasma concentration decay line was by 20%. Post-dialysis plasma concentration data suggest that the rate at which sotalol returns to plasma from body tissues appears to be the rate-controlling factor in the elimination of sotalol by haemodialysis.

Adult↗
PubMed1975

Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis.

An acute rise or decrease in parathyroid hormone (PTH) secretion was found in 30 patients, dialyzed with, respectively, low (5 mg/100 ml) or high (7.5 mg/100 ml) calcium concentration. The percentage changes were, respectively, +35% and -47% when a N-terminal antiserum measuring predominantly the glandular PTH was used. Only relatively small changes, respectively, +3% and -17%, were found using a C-terminal antiserum which detects preferentially smaller PTH fragments. Predialysis serum PTH concentration increases significantly with increasing duration of repetitive hemodialysis treatment using an intermediate (6 and 6.4 mg/100 ml) concentration of calcium in the dialysate. No such increase could be found in two other groups of patients treated with high-calcium (7.5 mg/100 ml) dialysis. Moreover, a significant but temporary decrease in predialysis serum PTH concentration occurred two months after a rise in dialysate calcium concentration from 6 to 7.5 mg/100 ml. Treatment with pharmacologic doses of vitamin D3 in selected patients (renal osterdystrophy or children) always resulted in a definite suppression of serum PTH concentration during 14 treatment periods in ten patients. After cessation of vitamin D3 treatment, serum PTH concentration returned to high levels in four out of five patients. These data fail to confirm the long-term involution of secondary hyperparathyroidism using high-calcium dialysis. Vitamin D treatment, however, results in a much more pronounced decrease in serum PTH concentrations, but sustained therapy is necessary.

Adolescent↗